Authors

Latest:

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.

Latest:

It is essential to ensure the safety profiles of potential COVID-19 therapies are supported by robust data so that healthcare providers and physicians can make appropriate, evidence-based decisions, writes Dr. Andrew Rut.

Latest:

A look at how Europe's new accelerated drug approval scheme can evolve existing review pathways for the better-and take a page from FDA

Latest:

Latest:

Pharma's challenge is to break the cycle of mistrust so that its pioneering work can fully reach patients in need, writes GSK's Murray Stewart.

Latest:

Highly skilled pharma staff are obliged to devote hours to routine administrative tasks updating product information. Technology can free them from this burden, writes Dr. Jutta Hohenhörst.

Latest:

Companies that want to tap into the full potential of Asia-Pac must boost the role of their regional headquarters.

Latest:

In the healthcare industry, “patient centricity” is like comfort food – everyone knows what it is, but it can mean very different things to different people.

Latest:

Sponsored contentThe term “patient centric” has become an almost catch-all term. Cheryl Lubbert looks at the broad range of its application. A review of how patient centricity is being applied shows that it is all of these things and more. A look at just a few different uses of the term shows the broad range of its application:

Latest:

FDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.

Latest:

 Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.    

Latest:

Technology is more critical than ever to help you keep your clinical trials on track during the era of COVID-19. Gain best practices about how to empower your remote workforce, get critical regulated documents electronically signed compliantly, and to create a safe and flexible remote patient-centric experience. Live: Wednesday, Jul. 15, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Jul. 15, 2021. Register free

Latest:

Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.

Latest:

If pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.

Latest:

Balancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.

Latest:

Increased scrutiny and new regulation have seen pharma’s relationship with key opinion leaders (KOLs) undergo a paradigm shift in recent years.

Latest:

Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.

Latest:

Outlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.

Latest:

The latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do the new rules mean for pharma players in the world’s third-largest market?

Latest:

The secret sauce for creating blockbuster brands has always been - and always will be - consistently exceptional team execution. Andy Mehrotra offers the recipe.

Latest:

Vice President, Psychiatry Marketing, Lundbeck US